14 Mar 2022
Chemomab Reports on Two Scientific Presentations that Support the Potential Therapeutic Utility of CM-101 in Systemic Sclerosis
Author: admintech | Filed under: Press Release—Translational Study Data Presented at 7th Systemic Sclerosis World Congress Confirms CCL24 is Elevated in Diffuse Cutaneous Systemic Sclerosis Patients; High CCL24 Serum Levels in Patients were Correlated with Greater Disease Activity and Worse Prognosis— —Chemomab Also Presented Data…